Marta Szwajca
Biographic Data
| ID | 7682033 |
|---|---|
| NAME | Marta Szwajca |
| GIVEN NAMES | Marta |
| FAMILY NAME | Szwajca |
| SIGNATURE | SZWAJCA M |
| AFFILIATIONS | Jagiellonian University |
| ORCID | 0000-0002-0666-0072 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Peripheral complement C3 and C4 are associated with clinical features of schizophrenia
Aim Schizophrenia is a severe psychiatric disorder with heterogeneous outcomes; factors such as anxiety, childhood trauma, and duration of untreated psychosis (DUP) may influence symptom severity and disease progression. Growing evidence highlights immune dysregulation—particularly alterations in complement components C3 and C4—in the pathophysiology of schizophrenia; however, findings regarding peripheral complement levels and their clinical ass…
GDNF and miRNA-29a as biomarkers in the first episode of psychosis
GDNF and miR-29a-3p are promising as biomarkers for understanding and addressing cognitive deficits in psychosis. This study links miRNA and MIF to premorbid adjustment and reveals GDNF's unique role in connection with childhood trauma
Immunological routine laboratory parameters at admission influence the improvement of positive symptoms in schizophrenia patients after pharmacological treatment
We show that objective markers can be obtained by testing immune and metabolic parameters from the patients' blood and may be added at a low cost to the standard care of schizophrenia patients in order to predict the outcome of pharmacological treatment
No prominent works on this page.
Immunological routine laboratory parameters at admission influence the improvement of positive symptoms in schizophrenia patients after pharmacological treatment
We show that objective markers can be obtained by testing immune and metabolic parameters from the patients' blood and may be added at a low cost to the standard care of schizophrenia patients in order to predict the outcome of pharmacological treatment
GDNF and miRNA-29a as biomarkers in the first episode of psychosis
GDNF and miR-29a-3p are promising as biomarkers for understanding and addressing cognitive deficits in psychosis. This study links miRNA and MIF to premorbid adjustment and reveals GDNF's unique role in connection with childhood trauma
Peripheral complement C3 and C4 are associated with clinical features of schizophrenia
Aim Schizophrenia is a severe psychiatric disorder with heterogeneous outcomes; factors such as anxiety, childhood trauma, and duration of untreated psychosis (DUP) may influence symptom severity and disease progression. Growing evidence highlights immune dysregulation—particularly alterations in complement components C3 and C4—in the pathophysiology of schizophrenia; however, findings regarding peripheral complement levels and their clinical ass…
Positive and Negative Syndrome Scale (3 works) · Psychosis (3 works) · Schizophrenia (object-oriented programming (3 works) · Clinical Psychology (2 works) · Clinical Psychology (2 works) · Cognition (2 works) · CTQ tree (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Psychiatry (2 works)